Pliant Therapeutics paused its phase 2b/3 trial of bexotegrast for idiopathic pulmonary fibrosis due to DSMB recommendations.

The FDA has approved Avtozma® (tocilizumab-anoh), a biosimilar to Actemra®, in both intravenous and subcutaneous formulations.

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...

Amgen AMGN reported fourth-quarter 2024 adjusted earnings of $5.31 per share, which beat the Zacks Consensus Estimate of ...

As COVID-19 raged around the world five years ago, London community nurse Beverly Summers found herself on the frontline of ...

Norfolk entrepreneur Tait Pollack from Norwich has credited sleep for saving his life after recovering from a life-threating illness following ...

Market focus will remain on earnings from major tech companies, in the wake of the sell-off in artificial ...

February is observed as American Heart Month, a period dedicated to raising awareness about heart health. The first American Heart ...

Results from a fourth cohort are expected in the second quarter of 2025. "Adding an additional dose group gives us ... among others Novo Nordisk and AstraZeneca. Nanexa's share is listed on ...

(RTTNews) - The U.S. Food and Drug Administration has approved AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU (fam-trastuzumab deruxtecan-nxki) for the treatment of adult ...